BERLIN: Scientists have identified highly effective antibodies against the new coronavirus, which they say may lead to the development of a passive vaccine for Covid-19. Unlike active vaccination, passive vaccination involves the administration of pre-made antibodies, which degrade after some time. However, the effect of a passive vaccine is almost …
Read More »Coronavirus Vaccine Update: Highly Effective Coronavirus Antibodies Identified That May Lead to Passive Covid-19 Vaccine |
BERLIN: Scientists have identified highly effective antibodies against the new coronavirus, which they say may lead to the development of a passive vaccine for Covid-19. Unlike active vaccination, passive vaccination involves the administration of pre-made antibodies, which degrade after some time. However, the effect of a passive vaccine is almost …
Read More »Donald Trump says he could reject stricter rules for COVID vaccine approvals
President Donald Trump noted that he could veto any tightening of US rules for emergency authorization of a coronavirus vaccine, a move that could heighten concerns that the race to find a Covid-19 injection will be over. is politicizing before the presidential elections. The Food and Drug Administration is expected …
Read More »Is the One-Shot COVID-19 vaccine enough? Johnson and Johnson begin the final test
Moderna Inc, Pfizer Inc, AstraZeneca vaccines require two injections separated by weeks (Representative) Chicago: Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot COVID-19 vaccine that would potentially simplify the delivery of millions of doses compared to major rivals using two doses. The company expects …
Read More »Johnson & Johnson launches massive global phase 3 clinical trial
In the midst of the race to develop a possible vaccine against the new coronavirus, pharmaceutical giant Johnson & Johnson has started phase three global trials of its single-dose Covid-19 vaccine with up to 60,000 volunteers from the US, South Africa, Argentina. , Brazil, Chile and Colombia. , Mexico and …
Read More »Bharat Biotech signs a license agreement with the University of Washington School of Medicine for the intranasal Covid vaccine
Bharat Biotech, a leading vaccine and biotherapeutics manufacturer, has entered into a licensing agreement with Washington University School of Medicine in St. Louis, Missouri, USA, for a single-dose intranasal vaccine for coronavirus disease. (Covid-19). Bharat Biotech owns the rights to distribute the vaccine in all markets except the United States, …
Read More »Bharat Biotech obtains the rights for the covid nasal vaccine technology, eyes 100 crore doses
Hyderabad-based Bharat Biotech and US biotech firm Precision Virologics jointly obtained the rights from Washington University School of Medicine in St. Louis for a novel chimpanzee adenovirus vaccine against COVID-19. Bharat Biotech will own the rights to distribute the nasal covid vaccine, subject to regulatory approvals, in all markets except …
Read More »UN chief criticizes countries for making ‘parallel agreements’ on vaccination against Covid-19 for their own population
With the Covid-19 pandemic soon reaching the grim milestone of one million deaths, UN Secretary-General Antonio Guterres on Tuesday rebuked countries that are making “side agreements” to have vaccines exclusively for their own populations, saying such “vaccination” is -Defeat. “” We are working to promote treatments and therapies as a …
Read More »Serum Institute of India begins manufacturing Codagenix COVID-19 nasal vaccine
Serum Institute of India has begun manufacturing the COVID-19 candidate vaccine developed by Codagenix Inc, the American biotech firm said in a statement. Nicknamed CDX-005, the coronavirus vaccine candidate has completed preclinical studies in animals. The company aims to begin the phase I clinical trial of its COVID-19 vaccine in …
Read More »India needs to invest between ₹ 3K-5K crore to give all Indians the Covid vaccine: President of Zydus Cadila
New Delhi: As the world waits with anticipation for the COVID-19 vaccine, Zydus Cadila Chairman Pankaj R Patel said India would have to invest between ₹3,000-5,000 crore to create additional facilities to manufacture a large number of vaccines needed for the Indian population. He also said that the vaccine alone …
Read More »